CombiMatrix: CombiMatrix Acquired By Invitae For $34.9M

Irvine-based CombiMatrix, which had developed genetic testing technology for the pediatric and prenatal disorder area, has been acquired by Invitae, in a deal worth approximately $34.9M in stock. Invitae, which is based in San Francisco, said the acquisition will bolster its efforts in the family and reproductive health genetic information area. CombiMatrix had provided providing genetic information for prenatal diagnosis, miscarriage analysis and diagnosis of pediatric developmental disorders, using single nucleotide polymorphism chromosomal microarray analysis and next generation sequencing. Publicly traded CombiMatrix will cease trading on the NASDAQ Capital Market as a result of the merger.